← Leaderboards
Shin-Heng Chiou
Rutgers Biomedical And Health Sciences
$1,162,209
Attributed
$1,364,052
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $700.6K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,364,052 · 2
By mechanism
R01$960,365 · 1
R21$403,687 · 1
Top collaborators
- Christian Hinrichs2 shared
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Steven K. Libutti$7,794,095
- Edmund C. Lattime$9,980,995
- Salma Jabbour$1,579,426
- Wei-Xing Zong$16,617,751
- Sunita Chaudhary$1,744,600
Others in their field
Other Rising Stars on “Cancer Cell”
- Cathryn Peltz · Henry Ford Health + Michigan State University Health Sciences$7,977,678
- Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research$7,024,010
- Christine O'Connell · H. Lee Moffitt Cancer Ctr & Res Inst$5,494,823
- Kenneth Schultz · Trethera Corporation$4,101,665
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
Research focus
Cancer CellCell LineIn VivoMalignant NeoplasmsExperimental StudyBindingGenesAffinityMediatingPlayCellsCancer TherapyAntigen TargetingCancer TypeCancer PatientCancer Institute Of New JerseyAntigen-Specific T CellsAntibodiesChimeric Antigen Receptor T CellsAntigensCell SurfaceChromatinChromatin ImmunoprecipitationAnti-Cancer
Grant awards (4)
Elucidation of hypoxia-induced metastatic reprogramming through the regulation of KDM8 function in pancreatic cancer$479,942
R01 · FY2025 · CA · contact PI
Developing TCR-T cell therapy in renal cell carcinoma$183,494
R21 · FY2025 · CA · contact PI
Elucidation of hypoxia-induced metastatic reprogramming through the regulation of KDM8 function in pancreatic cancer$480,423
R01 · FY2024 · CA · contact PI
Developing TCR-T cell therapy in renal cell carcinoma$220,193
R21 · FY2024 · CA · contact PI